Company Description
IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.
It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.
This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level.
The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services.
The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services.
It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE.
The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017.
The company is headquartered in Durham, North Carolina.
| Country | United States |
| Founded | 1982 |
| IPO Date | May 9, 2013 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 87,000 |
| CEO | Ari Bousbib |
Contact Details
Address: 2400 Ellis Road Durham, North Carolina 27703 United States | |
| Phone | 919-998-2000 |
| Website | iqvia.com |
Stock Details
| Ticker Symbol | IQV |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001478242 |
| CUSIP Number | 46266C105 |
| ISIN Number | US46266C1053 |
| Employer ID | 27-1341991 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Ari Bousbib | Chief Executive Officer and Chairman |
| Ronald E. Bruehlman | Executive Vice President and Chief Financial Officer |
| Eric M. Sherbet | Executive Vice President, General Counsel and Secretary |
| W. Richard Staub III | President of Research and Development Solutions |
| Kevin C. Knightly | President of Corporate Strategy and Enterprise Networks |
| Keriann Cherofsky | Senior Vice President, Corporate Controller and Chief Accounting Officer |
| Jim Berkshire | Executive Vice President of Global Technology and Operations |
| Dr. Jeffrey A. Spaeder M.D. | Senior Vice President, Global Chief Medical and Scientific Officer |
| Kerri Joseph | SVice President of Investment Relation and Treasury |
| Trudy Stein | Chief Human Resources Officer and Executive Vice President |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2024 | 8-K | Current Report |
| Mar 1, 2024 | 144 | Filing |
| Feb 29, 2024 | 144 | Filing |
| Feb 28, 2024 | 144 | Filing |
| Feb 23, 2024 | ARS | Filing |
| Feb 23, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Feb 23, 2024 | DEF 14A | Other definitive proxy statements |
| Feb 16, 2024 | 144 | Filing |
| Feb 16, 2024 | 144 | Filing |
| Feb 15, 2024 | 10-K | Annual Report |